| Recruitment status | No longer recruiting |
| Unique ID issued by UMIN | UMIN000020286 |
| Receipt No. | R000023423 |
| Official scientific title of the study | Evaluation of drug interactions of cytochrome P450 by single-substrate administrations and the cocktail method |
| Date of disclosure of the study information | 2015/12/21 |
| Last modified on | 2016/12/20 (Ver. 12) |
| Basic information | ||
| Official scientific title of the study | Evaluation of drug interactions of cytochrome P450 by single-substrate administrations and the cocktail method | |
| Title of the study (Brief title) | Evaluation of drug interactions of cytochrome P450 by single-substrate administrations and the cocktail method | |
| Region |
|
|
| Condition | ||
| Condition | drug interaction | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose of this study is to clarify the changes of cytochrome P450
(CYP) activities (1A2, 2C9, 2C19, 2D6) evaluated between single-probe administrations and cocktail method after administrations of a CYP-inducer and CYP inhibitors. |
| Basic objectives2 | Pharmacokinetics |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Pharmacokinetics of caffeine, losartan omeprazole, dextromethorphan |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | drugs(CYP inducer and inhibitor)
inducer : rifampicin 450 mg s.i.d for 6 days before trial inhibitor : cimetidine 400mg b.i.d for 2 days before trial, fluvoxamine 25 mg b.i.d for 2days before trial |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1 helthy male, over 20 years old
2 without hepatic disorder, renal disorder and disease under treatment 3 without medication allergy and idiosyncrasy 4 without drug dependence and alchol dependence 5 with consent to take part in this study by document |
|||
| Key exclusion criteria | 1 being unwellness
2 with abnormalities of bllod examination in advance 3 inadequateness to this study |
|||
| Target sample size | 24 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroshi Watanabe |
| Organization | Hamamatsu University School of Medicine |
| Division name | Department of Clinical Pharmacology and Therapetics |
| Address | 1-20-1, Hanadayama, Higashi-ku, Hamamatsu |
| TEL | 053-435-2385 |
| hwat@hama-med.ac.jp | |
| Public contact | |
| Name of contact person | Akio Hakamata |
| Organization | Hamamatsu University School of Medicine |
| Division name | Department of Clinical Pharmacology and Therapetics |
| Address | 1-20-1, Hanadayama, Higashi-ku, Hamamatsu |
| TEL | 053-435-2385 |
| Homepage URL | |
| hakamata@hama-med.ac.jp | |
| Sponsor | |
| Institute | Hamamatsu University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ministry of Education, Sports, Science, and Technology |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Department of Parmacy Practice and Science, School of PharmaceuticalaScience, University of Shizuoka |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | No longer recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023423 |